Atrin Pharmaceuticals
Mr. Rudnick has over 35 years of experience in executive-level strategy, finance, and management, including in biotech companies. He co-founded multiple companies, including CapGenic Advisors, LLC, and a number of start-ups, three of which grew to over $60 million in revenue before exiting. He is also a founder of one of the US’s leading entrepreneurial programs (MADV) at the Fox School of Business in Philadelphia. Working with businesses ranging from start-ups to Fortune 50 companies, Mr. Rudnick has developed extensive experience in senior merger, acquisition, capital formation, and licensing leadership. He also has substantial experience investing and guiding investments in entrepreneurial companies and has led capital formation totaling more than $3 billion over the last 15 years. Mr. Rudnick is affiliated with several angel groups, including Minority Angel Investment Network, Mid-Atlantic Bio Angels (which he co-founded), and Keiretsu Mid-Atlantic.
This person is not in the org chart
This person is not in any offices
Atrin Pharmaceuticals
Atrin Pharmaceuticals is a private biopharmaceutical company pioneering the discovery & development of proprietary molecules targeting DNA Damage and Response (DDR) pathways to treat a broad spectrum of cancers associated with synthetic lethality and the deregulated DNA Damage Response.